Edwards Lifesciences Corp (EW) Q3 2022 Earnings Call Transcript

Edwards Lifesciences Corp (NYSE:EW) Q3 2022 Earnings Conference Call October 27, 2022 5:00 PM ET

Company Participants

Mark Wilterding - VP, IR

Michael Mussallem - Chairman & CEO

Scott Ullem - Corporate VP & CFO

Bernard Zovighian - Corporate VP, Transcatheter Mitral & Tricuspid Therapies

Daveen Chopra - Corporate VP, Surgical Heart Valve Therapies

Larry Wood - Corporate VP, Transcatheter Aortic Valve Replacement

Conference Call Participants

Lawrence Biegelsen - Wells Fargo Securities

Robert Marcus - JPMorgan Chase & Co.

Joshua Jennings - Cowen and Company

Joanne Wuensch - Citigroup

Richard Newitter - Truist Securities

Frederick Wise - Stifel, Nicolaus & Company

Cecilia Furlong - Morgan Stanley

Philip Chickering - Deutsche Bank

Vijay Kumar - Evercore ISI

Travis Steed - Bank of America Merrill Lynch

Adam Maeder - Piper Sandler & Co.

Operator

Good afternoon, and welcome to the Edwards Lifesciences Third Quarter 2022 Results Conference Call. [Operator Instructions]. Please note that this conference is being recorded. I will now turn the conference over to our host, Mark Wilterding, Senior Vice President, Investor Relations and Treasurer. Thank you. You may begin.

Mark Wilterding

Thank you very much, Diego. And good afternoon, and thank you all for joining us. With me on today's call are Mike Mussallem, Chairman and Chief Executive Officer; and Scott Ullem, Chief Financial Officer. Also joining us for the Q&A portion of the call are Larry Wood, our global leader of TAVR; Bernard Zovighian, our global leader of TMTT; Daveen Chopra, our Global Leader of Surgical Structural Heart; and Katie Szyman, our global leader of Critical Care. Just after the close of regular trading, Edwards Lifesciences released third quarter 2022 financial results.

During today's call, management will discuss those results included in the press release and accompanying financial schedules and then use the remaining time for Q&A. Please note that management will be making forward-looking statements that are based on estimates, assumptions and projections. These statements include, but aren't limited to, financial guidance and expectations for longer-term growth opportunities, regulatory approvals, clinical trials, litigation, reimbursement, competitive matters and foreign currency fluctuations.

These statements speak only as of the date on which they were made, and Edwards does not undertake any obligation to update them after today. Additionally, the statements involve risks and uncertainties that could cause actual results to differ materially. Information concerning factors that could cause these differences and important product safety information may be found in the press release our 2021 annual report on Form 10-K and Edwards' other SEC filings, all of which are available on the company's website at edwards.com.